The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan

Introduction BAY 56-3722 (formerly BAY 38-3441) is a glycoconjugated campthotecin, which was considered an attractive drug to assess in colorectal cancer (CRC). Patient and methods Phase II study design evaluating the antitumor activity of BAY 56-3722 IV 320 mg/m(2) daily for 3 days every 3 weeks in...

Descripción completa

Detalles Bibliográficos
Autores principales: Slingerland, Marije, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/
https://www.ncbi.nlm.nih.gov/pubmed/21547368
http://dx.doi.org/10.1007/s10637-011-9679-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/
https://www.ncbi.nlm.nih.gov/pubmed/21547368
http://dx.doi.org/10.1007/s10637-011-9679-4

Ejemplares similares